Cost Of New Drug Development Pushed To $2.6 Bil. By High Failure Rate – Study
This article was originally published in The Pink Sheet Daily
Executive Summary
The Tufts Centers for the Study of Drug Development updates its often-quoted drug development cost benchmark in a study released Nov. 18.
You may also be interested in...
Latest R&D Spending Benchmark Study Puts Cancer Drug Costs At $648M
Estimate in JAMA paper is significantly lower than often-cited $2.6bn in research and development costs projected in a 2014 study by Tufts Center for the Study of Drug Development.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.
Xtandi Pricing and Patents: Alternatives To March-In Urged To Lower Medicare, Medicaid Costs
The timing of the request, with Xtandi’s loss of exclusivity on the horizon, could be explained by the concern that a change in the US presidential administration in 2025 may limit the prospects for near-term relief.